<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7357070</article-id><article-id pub-id-type="doi">10.3390/molecules25122944</article-id><article-id pub-id-type="publisher-id">molecules-25-02944</article-id><article-categories><subj-group subj-group-type="heading"><subject>Communication</subject></subj-group></article-categories><title-group><article-title>Data and Text Mining Help Identify Key Proteins Involved in the Molecular Mechanisms Shared by SARS-CoV-2 and HIV-1</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3723-7832</contrib-id><name><surname>Tarasova</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="af1-molecules-25-02944">1</xref><xref rid="c1-molecules-25-02944" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3177-6237</contrib-id><name><surname>Ivanov</surname><given-names>Sergey</given-names></name><xref ref-type="aff" rid="af1-molecules-25-02944">1</xref><xref ref-type="aff" rid="af2-molecules-25-02944">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0339-8478</contrib-id><name><surname>Filimonov</surname><given-names>Dmitry A.</given-names></name><xref ref-type="aff" rid="af1-molecules-25-02944">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7937-2621</contrib-id><name><surname>Poroikov</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="af1-molecules-25-02944">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Geronikaki</surname><given-names>Athina</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Maigret</surname><given-names>Bernard</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-25-02944"><label>1</label>Department for Bioinformatics, Institute of Biomedical Chemistry, 107076 Moscow, Russia; <email>smivanov7@gmail.com</email> (S.I.); <email>dmitry.filimonov@ibmc.msk.ru</email> (D.A.F.); <email>vladimir.poroikov@ibmc.msk.ru</email> (V.P.)</aff><aff id="af2-molecules-25-02944"><label>2</label>Department of Bioinformatics of Pirogov Russian National Research Medical University, 107076 Moscow, Russia</aff><author-notes><corresp id="c1-molecules-25-02944"><label>*</label>Correspondence: <email>olga.a.tarasova@gmail.com</email>; Tel.: +7-499-255-30-29</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><volume>25</volume><issue>12</issue><elocation-id>2944</elocation-id><history><date date-type="received"><day>04</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Viruses can be spread from one person to another; therefore, they may cause disorders in many people, sometimes leading to epidemics and even pandemics. New, previously unstudied viruses and some specific mutant or recombinant variants of known viruses constantly appear. An example is a variant of coronaviruses (CoV) causing severe acute respiratory syndrome (SARS), named SARS-CoV-2. Some antiviral drugs, such as remdesivir as well as antiretroviral drugs including darunavir, lopinavir, and ritonavir are suggested to be effective in treating disorders caused by SARS-CoV-2. There are data on the utilization of antiretroviral drugs against SARS-CoV-2. Since there are many studies aimed at the identification of the molecular mechanisms of human immunodeficiency virus type 1 (HIV-1) infection and the development of novel therapeutic approaches against HIV-1, we used HIV-1 for our case study to identify possible molecular pathways shared by SARS-CoV-2 and HIV-1. We applied a text and data mining workflow and identified a list of 46 targets, which can be essential for the development of infections caused by SARS-CoV-2 and HIV-1. We show that SARS-CoV-2 and HIV-1 share some molecular pathways involved in inflammation, immune response, cell cycle regulation.</p></abstract><kwd-group><kwd>data mining</kwd><kwd>text mining</kwd><kwd>virus&#x02013;host interactions</kwd><kwd>SARS</kwd><kwd>SARS-CoV-2</kwd><kwd>HIV-1</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-25-02944"><title>1. Introduction</title><p>Studying viruses that infect human beings is vital because viral infections can spread within the global population. For several centuries, measles, poliomyelitis, rotavirus, human immunodeficiency virus, and different respiratory viruses, including influenza, parainfluenza, adenoviruses, and coronaviruses, have attacked humanity. Such viruses as HIV-1 earlier or SARS-CoV-2 nowadays cause the socially significant epidemic or even pandemic diseases [<xref rid="B1-molecules-25-02944" ref-type="bibr">1</xref>,<xref rid="B2-molecules-25-02944" ref-type="bibr">2</xref>].</p><p>SARS-CoV-2 causes severe acute respiratory syndrome and leads to diverse complications, being especially dangerous for people with different comorbidities. Starting from the end of January, COronaVIrus Disease 2019 (COVID-19) has spread all over the world and become a source of fear and sorrow for millions of people. The investigation of the interaction of SARS-CoV-2 with the human body is essential because such information will contribute to the development of effective therapeutic approaches.</p><p>According to the study by Gordon [<xref rid="B3-molecules-25-02944" ref-type="bibr">3</xref>], the profile of SARS-CoV-2&#x02013;host interactions is similar to those of involving various viruses, such as West Nile virus, human papillomaviruses, Zika, Dengue, Ebola viruses, and HIV.</p><p>The dangerous spreading of SARS-CoV-2 has given rise to multiple attempts of repurposing of drugs initially developed against other viruses, such as hepatitis C, HIV-1, influenza, etc., along with host-targeted drugs such as hydroxychloroquine and azithromycin [<xref rid="B4-molecules-25-02944" ref-type="bibr">4</xref>,<xref rid="B5-molecules-25-02944" ref-type="bibr">5</xref>,<xref rid="B6-molecules-25-02944" ref-type="bibr">6</xref>,<xref rid="B7-molecules-25-02944" ref-type="bibr">7</xref>,<xref rid="B8-molecules-25-02944" ref-type="bibr">8</xref>,<xref rid="B9-molecules-25-02944" ref-type="bibr">9</xref>].</p><p>Overcoming the challenges of novel viral infections requires a fast and effective search for novel therapeutic approaches. A perspective strategy is focused on finding proteins involved in the infection process caused by both studied and well-known agents using published articles and other available information. The identified proteins can then be used as pharmaceutical targets. In this study, we aimed at evaluating such approach by considering the extensively explored HIV-1 virus [<xref rid="B1-molecules-25-02944" ref-type="bibr">1</xref>] and new dangerous virus SARS-CoV-2 [<xref rid="B2-molecules-25-02944" ref-type="bibr">2</xref>].</p><p>There are a few experimental and computational approaches examining the possibility of usage of known antiviral drugs, including those employed for the treatment of viral hepatitis C and antiretroviral drugs, to treat SARS-CoV-2 [<xref rid="B7-molecules-25-02944" ref-type="bibr">7</xref>,<xref rid="B8-molecules-25-02944" ref-type="bibr">8</xref>,<xref rid="B9-molecules-25-02944" ref-type="bibr">9</xref>]. There are several studies describing the treatment of SARS-CoV-2 using antiretroviral drugs, such as remdesivir [<xref rid="B10-molecules-25-02944" ref-type="bibr">10</xref>], lopinavir/ritonavir, and darunavir [<xref rid="B9-molecules-25-02944" ref-type="bibr">9</xref>,<xref rid="B11-molecules-25-02944" ref-type="bibr">11</xref>]. The molecular mechanism of action of lopinavir/ritonavir has been discussed [<xref rid="B12-molecules-25-02944" ref-type="bibr">12</xref>,<xref rid="B13-molecules-25-02944" ref-type="bibr">13</xref>,<xref rid="B14-molecules-25-02944" ref-type="bibr">14</xref>]. Their application for the treatment of COVID-19 as monotherapies [<xref rid="B12-molecules-25-02944" ref-type="bibr">12</xref>] or in combination with other drugs [<xref rid="B13-molecules-25-02944" ref-type="bibr">13</xref>] has been shown.</p><p>While the mechanisms of action of antiretroviral drugs against COVID-19 are under investigation, there are data suggesting that SARS-CoV-2 may affect the immune system [<xref rid="B15-molecules-25-02944" ref-type="bibr">15</xref>]. Lymphopenia can be present in patients with COVID-19 [<xref rid="B16-molecules-25-02944" ref-type="bibr">16</xref>] and can be associated with disease progression [<xref rid="B16-molecules-25-02944" ref-type="bibr">16</xref>].</p><p>The analysis of the available information provides (1) data on repurposing of antiretroviral drugs against SARS-CoV-2, (2) data showing similarity of interaction profiles between SARS-CoV-2 and human and HIV-1-human, (3) data indicating common pathophysiological mechanisms between SARS-CoV-2 and HIV-1 infections. In addition, there are a lot of data on the molecular mechanisms of HIV infection, regarding multiple pathways of virus&#x02013;host interactions and the development of novel therapeutic approaches. Text and data mining approaches can be helpful for fast and accurately extracting information about chemical compounds and their biological activities, as well as proteins associated with molecular mechanisms of disease development [<xref rid="B17-molecules-25-02944" ref-type="bibr">17</xref>,<xref rid="B18-molecules-25-02944" ref-type="bibr">18</xref>]. In this study, we applied text and data mining approaches to identify possible molecular pathways shared by HIV-1 and SARS-CoV-2. Our hypothesis was that the search for similar molecular mechanisms shared by SARS-CoV-2 and HIV-1 could shed light on novel potential therapeutic approaches for the treatment of COVID-19.</p><p>SARS-CoV-2 and HIV-1 belong to different virus classes, according to Baltimore classification [<xref rid="B19-molecules-25-02944" ref-type="bibr">19</xref>]. Data on the homology between SARS-CoV-2 and HIV-1 are controversial [<xref rid="B20-molecules-25-02944" ref-type="bibr">20</xref>]. Besides, they use different cells to replicate in the human body. HIV-1 uses the receptors CCR5 or CXCR4 to infect CD4 T cells [<xref rid="B21-molecules-25-02944" ref-type="bibr">21</xref>,<xref rid="B22-molecules-25-02944" ref-type="bibr">22</xref>], while SARS-CoV-2 uses ACE2 to infect the cells of heart, lungs, kidneys, and gastrointestinal tract [<xref rid="B23-molecules-25-02944" ref-type="bibr">23</xref>].</p><p>There are therapeutic strategies to combat HIV-1 infection in addition to combination antiretroviral therapy, which is currently used to treat HIV-infection [<xref rid="B24-molecules-25-02944" ref-type="bibr">24</xref>]. Other approaches to combat HIV-1 infection include novel strategies such as disrupting the <italic>CCR5</italic> gene in human hematopoietic stem/progenitor cells (HSCs) [<xref rid="B25-molecules-25-02944" ref-type="bibr">25</xref>] using zinc finger nuclease-mediated CCR5 knockout, or in CD4<sup>+</sup> T cells or HSCs using CRISPR/Cas9 genome editing [<xref rid="B26-molecules-25-02944" ref-type="bibr">26</xref>,<xref rid="B27-molecules-25-02944" ref-type="bibr">27</xref>]. Viral RNA genome degradation and inhibition of viral gene expression is another promising strategy to prevent the replication of SARS-CoV-2 [<xref rid="B28-molecules-25-02944" ref-type="bibr">28</xref>] and HIV-1 [<xref rid="B29-molecules-25-02944" ref-type="bibr">29</xref>]. The search for potent low-molecular-weight drugs targeting SARS-CoV-2 is ongoing, but some currently applied treatment strategies include the use of some known drugs such as remdesivir, chloroquine, umifenovir, and some antiretroviral drugs (darunavir, lopinavir in combination with ritonavir) [<xref rid="B30-molecules-25-02944" ref-type="bibr">30</xref>].</p><p>The therapeutic effects of medicines applied for the treatment of rheumatoid arthritis [<xref rid="B31-molecules-25-02944" ref-type="bibr">31</xref>] along with those of some other drugs such as antiretroviral drugs (darunavir, lopinavir in combination with ritonavir) [<xref rid="B32-molecules-25-02944" ref-type="bibr">32</xref>] on SARS-CoV-2 have generated interest in identifying similar mechanisms of viral infection shared by SARS-CoV-2 and HIV-1, in particular their effects on the host&#x02019;s organism. Another important fact is that SARS-CoV-2 can cause serious complications in people with comorbidities [<xref rid="B11-molecules-25-02944" ref-type="bibr">11</xref>,<xref rid="B33-molecules-25-02944" ref-type="bibr">33</xref>,<xref rid="B34-molecules-25-02944" ref-type="bibr">34</xref>,<xref rid="B35-molecules-25-02944" ref-type="bibr">35</xref>], in particular, by causing the so-called cytokine release syndrome [<xref rid="B33-molecules-25-02944" ref-type="bibr">33</xref>].</p><p>In this study, we will also discuss the role of the identified virus&#x02013;host interactions in the pathogenesis of SARS-CoV-2 and the molecular mechanisms shared by HIV-1 and SARS-CoV-2.</p></sec><sec sec-type="results" id="sec2-molecules-25-02944"><title>2. Results</title><p>We collected a set of proteins, identified in previous papers, relevant to both HIV&#x02013;host and SARS-CoV-2&#x02013;host interaction. We searched them using different protein and gene databases, including UniProt, KEGG, DisGeNet, and Integrity [<xref rid="B36-molecules-25-02944" ref-type="bibr">36</xref>,<xref rid="B37-molecules-25-02944" ref-type="bibr">37</xref>,<xref rid="B38-molecules-25-02944" ref-type="bibr">38</xref>,<xref rid="B39-molecules-25-02944" ref-type="bibr">39</xref>]. Some examples of the most significant proteins that play a role in both HIV-1 and SARS-CoV-2 infections are presented in <xref rid="molecules-25-02944-t001" ref-type="table">Table 1</xref>.</p><p>For a full list, see <xref ref-type="app" rid="app1-molecules-25-02944">Supplementary Materials, Table S1</xref>.</p><p>The possible role of the identified proteins in the molecular mechanisms of these infections was analyzed.</p><p>Besides the interpretation of the role of individual proteins in SARS-CoV-2 and HIV-1 infections, we performed KEGG [<xref rid="B37-molecules-25-02944" ref-type="bibr">37</xref>] pathway enrichment analysis using genes related to the human proteins found in UniProt: we obtained 46 proteins (see Materials and Methods). Then, we manually inspected the positions of the genes in the maps of enriched pathways and filtered out non-relevant pathways. For example, the FoxO signaling pathway was identified by the enrichment analysis, but FOXO transcriptional factors were not among those 46 proteins; thus, we considered the pathway as non-relevant. Finally, we obtained a list of 27 pathways (<xref ref-type="fig" rid="molecules-25-02944-f001">Figure 1</xref>):</p><p>The significant number of signaling pathways related to the immune system and the Toll-like receptor signaling pathway included the largest number of proteins identified. There were several pathways related to various viruses. This means that some of the 46 proteins are involved in pathways shared by SARS-CoV-2, HIV-1, and other viruses. This result was confirmed by a disease enrichment analysis, which was performed based on gene&#x02013;disease associations using the DisGeNet database [<xref rid="B38-molecules-25-02944" ref-type="bibr">38</xref>]. Various viral infections and related diseases, including SARS-CoV-2 and HIV-1 infections, were among the top enriched diseases (see <xref ref-type="app" rid="app1-molecules-25-02944">Supplementary Materials, Figure S1</xref>).</p><p>To check whether other viruses have similar interactomic profiles to that of SARS-CoV-2, we also evaluated texts associated with Dengue virus and determined an overlap between the proteins relevant to Dengue&#x02013;host interactions and those relevant to SARS&#x02013;CoV-2&#x02013;host interactions. We found 32 human proteins, which can be involved in both SARS-CoV-2&#x02013;host and Dengue&#x02013;host interactions. For them, we prepared a list of related pathways. We observed a similar profile of molecular pathways for proteins shared by Dengue virus and SARS-CoV-2 to that for proteins shared by HIV-1 and SARS-CoV-2 (<xref ref-type="fig" rid="molecules-25-02944-f002">Figure 2</xref>).</p><p>Nevertheless, we found differences in the number of pathways related to the immune system, in particular in the number of proteins associated with the Toll-like receptors-related pathway; this is consistent with other studies showing the involvement of the immune system in SARS-CoV-2 disease progression [<xref rid="B15-molecules-25-02944" ref-type="bibr">15</xref>,<xref rid="B16-molecules-25-02944" ref-type="bibr">16</xref>]. Also, some of the pathways, for instance, necrosis, apoptosis, and autophagy pathways, common to SARS-CoV-2&#x02013;host and HIV-1&#x02013;host interactions were not found in the list of pathways related to SARS-CoV-2&#x02013;host and Dengue&#x02013;host interactions. This information on proteins involved in the interactions between various viruses and the human organism can be helpful for the future development of therapeutic strategies against these viruses.</p><p>In addition, by examining the 46 proteins related to both SARS-CoV-2-host and HIV-1-host interactions in the Integrity database, we identified the main processes associated with targets currently validated for the treatment of different pathological conditions and diseases. We discuss our results below.</p></sec><sec sec-type="discussion" id="sec3-molecules-25-02944"><title>3. Discussion</title><p>By a literature review and a pathway enrichment analysis, we identified some key proteins and pathways which may be proposed as essential for both SARS-CoV-2 and HIV-1 infections. For instance, the protein AIP4 may play a role in inflammation, and the interaction of SARS-CoV-2 with this protein may downregulate the host&#x02019;s interferon response [<xref rid="B40-molecules-25-02944" ref-type="bibr">40</xref>]. This would lead to the disruption of the host&#x02019;s immune response. A similar mechanism was reported for HIV-1 [<xref rid="B41-molecules-25-02944" ref-type="bibr">41</xref>].</p><p>It has been shown that protein beclin 1 induces autophagy in immune cells, which negatively regulates the host&#x02019;s immune defense mechanisms. The possible role of beclin-1 in autophagy as one of the molecular mechanisms of viral pathogenesis was discussed for both coronaviruses and HIV-1 [<xref rid="B42-molecules-25-02944" ref-type="bibr">42</xref>,<xref rid="B43-molecules-25-02944" ref-type="bibr">43</xref>]. The inhibition of beclin-1 can help to reduce viral replication of MERS-CoV (Middle East respiratory syndrome coronavirus) [<xref rid="B44-molecules-25-02944" ref-type="bibr">44</xref>]. Despite these findings, it is supposed that the viruses can either escape autophagy or use the autophagic machinery for their own replication [<xref rid="B45-molecules-25-02944" ref-type="bibr">45</xref>]. That is why the strategy of inhibition of the proteins included in the autophagic machinery is not considered as a promising one to combat viral infections including HIV-1 infection and COVID-19 [<xref rid="B45-molecules-25-02944" ref-type="bibr">45</xref>].</p><p>The proteins cathepsin B and L, which are endosomal proteases, are responsible for viral fusion and the release of the viral genome into the cytoplasm of human cells [<xref rid="B46-molecules-25-02944" ref-type="bibr">46</xref>]. The dependence of SARS-CoV-2 entry on cathepsin B was shown in the study by Hoffman et al. [<xref rid="B47-molecules-25-02944" ref-type="bibr">47</xref>] and discussed in also elsewhere [<xref rid="B47-molecules-25-02944" ref-type="bibr">47</xref>,<xref rid="B48-molecules-25-02944" ref-type="bibr">48</xref>]. This process was shown to be pH-dependent. Divani et al. [<xref rid="B48-molecules-25-02944" ref-type="bibr">48</xref>] suggested that the Spike (S) protein of the SARS-CoV-2 can be &#x0201c;primed&#x0201d; by cathepsins B and L, which is essential for their penetration into the cells. In the study by Yoshii. et al. [<xref rid="B49-molecules-25-02944" ref-type="bibr">49</xref>], the authors claimed that cathepsin B is involved in CD4-independent entry of HIV-1, i.e., this type of entry can be used by HIV-1 variants that do not require CD4 for infection [<xref rid="B49-molecules-25-02944" ref-type="bibr">49</xref>]. There is evidence that an interaction of SARS-CoV-2 with cathepsin L is essential for SARS-CoV-2 entry [<xref rid="B50-molecules-25-02944" ref-type="bibr">50</xref>]. Selective inhibitors of cathepsin L can be considered for the therapy of COVID-19 [<xref rid="B51-molecules-25-02944" ref-type="bibr">51</xref>]. The authors suggest the usage of selective cathepsin L inhibitors because active cathepsin S can assist viral release and MHC-I- and MHC-II-mediated antigen presentation as well as T-cell activation, which is important for protective immunity against SARS-CoV-2 and other infections. It is interesting that for herpesviruses, the role of cathepsin L in releasing viral particles was reported [<xref rid="B52-molecules-25-02944" ref-type="bibr">52</xref>], giving rise to the hypothesis that therapeutic strategies directed to inhibiting pathways associated with cathepsin L can be beneficial for non-specific antiviral activity. Cathepsin B is also associated with the release of HIV-1 particles in blood monocyte-derived macrophages [<xref rid="B53-molecules-25-02944" ref-type="bibr">53</xref>]. Additionally, it was shown that secretion of cathepsin B by HIV-infected macrophages leads to neuronal internalization and induces the progression of neuronal dysfunctions [<xref rid="B54-molecules-25-02944" ref-type="bibr">54</xref>,<xref rid="B55-molecules-25-02944" ref-type="bibr">55</xref>]. Therefore, cathepsin B expressed in different tissues is involved in several different molecular pathways of disease progression.</p><p>E3 ubiquitin ligase TRIM25 participates in the regulation of the antiviral innate immunity [<xref rid="B56-molecules-25-02944" ref-type="bibr">56</xref>,<xref rid="B57-molecules-25-02944" ref-type="bibr">57</xref>]. In particular, the SARS-CoV nucleocapsid protein, which has over 90% identity to that of SARS-CoV-2 [<xref rid="B58-molecules-25-02944" ref-type="bibr">58</xref>] was found to bind TRIM25, thereby inhibiting type 1 interferon production [<xref rid="B56-molecules-25-02944" ref-type="bibr">56</xref>]. TRIM25 was also shown to be required for the activity of a type I interferon-inducible host factor ZAP, which specifically inhibits the replication of certain viruses, including HIV-1, Sindbis virus, and Ebola virus [<xref rid="B57-molecules-25-02944" ref-type="bibr">57</xref>].</p><p>Some proteins, such as interferon gamma, interferon regulator factor 3, interleukin 2, matrix metalloproteinases, are responsible for the immune response or inflammation [<xref rid="B59-molecules-25-02944" ref-type="bibr">59</xref>,<xref rid="B60-molecules-25-02944" ref-type="bibr">60</xref>]. Therefore, these proteins should be involved in specific or non-specific antiviral or inflammatory response. An increase of interleukins in the blood plasma occurs in response to the infection, especially it can be observed during viral infections. SARS-CoV-2 affects the immune response, leading to a significant increase of chemokines and cytokines. To combat the cytokine storm in patients with COVID-19, several anti-rheumatic medicines, chloroquine, hydroxychloroquine, as well as JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-&#x003b1; agents, and corticosteroids are considered [<xref rid="B59-molecules-25-02944" ref-type="bibr">59</xref>]. The interleukin-6 receptor antagonist Tocilizumab is described as one of the promising drugs to combat the cytokine storm [<xref rid="B59-molecules-25-02944" ref-type="bibr">59</xref>]. The development of the cytokine storm in the patients infected by HIV-1 was shown [<xref rid="B61-molecules-25-02944" ref-type="bibr">61</xref>].</p><p>Interestingly, the role of the c3-complement system activation in SARS-CoV-1, SARS-CoV-2-related disorders and HIV-related comorbidities was discussed [<xref rid="B62-molecules-25-02944" ref-type="bibr">62</xref>,<xref rid="B63-molecules-25-02944" ref-type="bibr">63</xref>,<xref rid="B64-molecules-25-02944" ref-type="bibr">64</xref>,<xref rid="B65-molecules-25-02944" ref-type="bibr">65</xref>]. According to our results, complement c3 is involved in both inflammation and immune response processes, besides its role as a complement activation. An attempt to combat COVID-19 using the compstatin-based complement c3 inhibitor AMY-101 has been shown recently [<xref rid="B65-molecules-25-02944" ref-type="bibr">65</xref>], resulting in a good clinical response. The involvement of c3 complement in the mannose binding lectin-pathway (MBL) was shown during membrane attack complex (MAC) formation, leading to cell lysis and death [<xref rid="B66-molecules-25-02944" ref-type="bibr">66</xref>] of HIV-infected patients.</p><p>The genes encoding the proteins presented in <xref rid="molecules-25-02944-t001" ref-type="table">Table 1</xref> are expressed widely or ubiquitously. Therefore, they can participate in similar pathways during both SARS-CoV-2 and HIV-1 infections, despite the fact that SARS-CoV-2 and HIV-1 use different cell types for their replication, which indicates different molecular basis for the progression of their associated diseases. Most of the proteins identified are <italic>Homo sapiens</italic> proteins. For them, similar or identical molecular mechanisms of pathological processes during HIV-1 and COVID-19 can be proposed. This observation confirms the reliability of our approach for the extraction of data on proteins involved in the interaction of the host with either SARS-CoV-2 or HIV-1.</p><p>When we manually checked about 100 named entities (NE), we found 10 NE; and the lexical meaning of them was not related to known proteins but it was associated with the biological object, such as a virus, an organism, etc. Therefore, about 90% of the proteins found using our text and data mining algorithm can be considered as potential targets involved in the pathogenesis of both SARS-CoV-2 and HIV-1 infections.</p><p>Pathway enrichment analysis can help to identify a role of some signaling pathways in both HIV-1 ad SARS-CoV-2 infection. To perform the pathway enrichment analysis, first we manually mapped the initial entities, extracted by text mining, to UniProt Accession numbers. This process allowed us to collect a list of 46 human proteins. The Toll-like receptor-signaling pathway has the highest number of proteins related to immune system pathways and found to appear in both SARS-CoV-2 and HIV-1 infections (<xref ref-type="fig" rid="molecules-25-02944-f003">Figure 3</xref>). </p><p>Toll-like receptors 3 (TLR3) and 7 (TLR7) play an important role in the innate immune response against HIV-1 and SARS-CoV-2 [<xref rid="B67-molecules-25-02944" ref-type="bibr">67</xref>,<xref rid="B68-molecules-25-02944" ref-type="bibr">68</xref>,<xref rid="B69-molecules-25-02944" ref-type="bibr">69</xref>,<xref rid="B70-molecules-25-02944" ref-type="bibr">70</xref>,<xref rid="B71-molecules-25-02944" ref-type="bibr">71</xref>]. The polymorphism rs3775291 of the TLR3 receptor is associated with protection against HIV-1 [<xref rid="B67-molecules-25-02944" ref-type="bibr">67</xref>,<xref rid="B68-molecules-25-02944" ref-type="bibr">68</xref>]. TLR3 agonists increase the anti-HIV immune response induced by vaccination [<xref rid="B69-molecules-25-02944" ref-type="bibr">69</xref>]. TLR7 agonists increase the anti-HIV-1 immune response, the activation of HIV-1 expression, and the inhibition of HIV-1 replication, which may help to treat latent infections [<xref rid="B70-molecules-25-02944" ref-type="bibr">70</xref>]. The role of TLR3 and TLR7 in the pathogenesis of COVID-19 is discussed in the study by Sallenave [<xref rid="B71-molecules-25-02944" ref-type="bibr">71</xref>]. </p><p>Based on 46 human proteins, for which records were found in KEGG, we identified the biological processes related to diseases and the pathological conditions associated with these proteins using the Integrity database. We analyzed the sets of currently validated targets for the treatment of certain diseases and pathological conditions. According to these results, the majority of proteins are related to inflammation, autoimmune disorders and cancer (<xref ref-type="fig" rid="molecules-25-02944-f004">Figure 4</xref>).</p><p>It seems surprising that most of the found targets of existing drugs are not related to infectious diseases but, rather, are associated with inflammation, cancer, or immune disorders. However, since we analyzed virus&#x02013;host interactions, we could expect that SARS-CoV-2 and HIV-1 interaction with the host would be associated with processes like inflammation and those that affect the host immune system. The association between cancer development and inflammation has been discussed in several studies [<xref rid="B72-molecules-25-02944" ref-type="bibr">72</xref>,<xref rid="B73-molecules-25-02944" ref-type="bibr">73</xref>,<xref rid="B74-molecules-25-02944" ref-type="bibr">74</xref>,<xref rid="B75-molecules-25-02944" ref-type="bibr">75</xref>]. Moreover, the role of the targets associated with autoimmune diseases in the development of cancer has been described [<xref rid="B74-molecules-25-02944" ref-type="bibr">74</xref>]. Based on the analysis of the targets strongly related to the found conditions according to the Clarivate Analytics Integrity database [<xref rid="B39-molecules-25-02944" ref-type="bibr">39</xref>]&#x02014;provided in the <xref ref-type="app" rid="app1-molecules-25-02944">Supplementary Materials (Table S2)</xref>&#x02014;we identified three main groups of proteins. The first group contains interleukins (IL), interferon (IFN), interferon regulatory factor (IRF), IL6, IL8, IL12a, IL12b, IL18, IRF3. For these proteins, their role in inflammation and the immune response during infection is well studied [<xref rid="B76-molecules-25-02944" ref-type="bibr">76</xref>]. The second group contains a few proteins, such as the Toll-like receptors (TLR) TLR3 and TLR7, whose role in the immune response is described above. The third group contains some transcription factors and kinases which play a role in various molecular processes that are related to the inflammation response. They also can be important for the development of cancer. Regarding pathological conditions, in general, the results found using Integrity are very similar to those found using UniProt and KEGG. Still, an interpretation of the results collected from Integrity can help to better understand the effectiveness of approved drugs for the treatment of SARS-Co-V2 when specific antiviral medicines are not known.</p><p>The obtained results were confirmed by disease enrichment analysis based on gene&#x02013;disease associations using the DisGeNet database. We manually analyzed the top 30 enriched disease terms and classified them in four groups (see <xref ref-type="app" rid="app1-molecules-25-02944">Supplementary Materials, Figure S1</xref>). The first group includes 12 terms related to viruses and bacteria, e.g., SARS, HIV infections, hepatitis B and C, cytomegalovirus infections, influenza, tuberculosis, and others. The second group is related to inflammatory respiratory diseases: asthma, chronic obstructive airway disease, and pneumonia. The third group is related to cancer diseases, whereas the fourth group includes all other diseases, which are associated with inflammation, e.g., atherosclerosis, systemic lupus erythematosus, and rheumatoid arthritis. All 46 proteins appeared to be associated with at least one of the selected diseases, and the cytokines CXCL8, IL6, TNF were associated with all of them.</p><p>Additionally, we provide the full list of proteins related to the development of SARS-CoV-1 infection only in <xref ref-type="app" rid="app1-molecules-25-02944">Table S3 of the Supplementary Materials</xref>.</p><p>Summarizing our findings based on the analysis of the literature and on data retrieved from biological databases, we can define groups of proteins, which can be essential for both SARS-CoV-2-host and HIV-1-host interactions. The first group represents proteins responsible for viral entry in human cells, which are the same for HIV-1 and SARS-CoV-2 as well as for some other viruses. The second group of proteins is associated with the host&#x02019;s immune response to virus invasion of the cells; HIV-1 or SARS-CoV-2 interaction with these host proteins will lead to immune suppression. In addition, there are a few proteins that were found in just one or two publications but are important for processes such as blood coagulation. Third, some viral proteins can interact with human proteins in a close manner or share some similar structural motifs and can have the same effect on protein&#x02013;host interaction. </p></sec><sec id="sec4-molecules-25-02944"><title>4. Materials and Methods</title><p>We applied text and data mining algorithms to extract from publications a list of proteins relevant to virus&#x02013;host interactions common for HIV-1 and SARS-CoV-2. For this purpose, we performed several stages of text processing and data analysis (<xref ref-type="fig" rid="molecules-25-02944-f005">Figure 5</xref>).</p><p>In the first stage, we collected abstracts and full texts from NCBI PubMed and NCBI PubMed Central (PMC) repositories. We used the application-programming interface (API) available for PubMed and PMC, based on query allowing automated filtering of relevant papers. PubMed contains over 27 million articles, and PMC includes several million articles; for some of them (the so-called Open Access (OA) subset), it is possible to retrieve full texts in a machine-readable format (Extensible Markup Language, XML). We used PubMed and the Open Access Subset of PMC for our computational experiments. Relevant documents were selected based on the following combination of keywords: &#x0201c;HIV-1 AND virus&#x02013;host interactions&#x0201d;, &#x0201c;SARS AND virus&#x02013;host interactions,&#x0201d; &#x0201c;SARS-CoV-2 AND virus&#x02013;host interactions&#x0201d;. The queries were built using Python 3.7 scripts. We obtained the list of the identifiers of articles in PubMed electronic library (PMIDs) or the identifiers of NCBI PubMed Central (PMCIDs). The queries allowed identifying over 200 PMIDs and over 6000 PMIDs in the PubMed database relevant to SARS&#x02013;host and SARS-CoV-2-host interactions and HIV1&#x02013;host interactions, respectively. We named these corpora of texts as &#x0201c;SARS-PubMed&#x0201d; and &#x0201c;HIV-PubMed&#x0201d;. Over 180 PMCIDs were retrieved for SARS&#x02013;host and SARS-CoV-2&#x02013;host interactions, and over 57,000 PMCIDs were collected for HIV-1&#x02013;host interactions using an automated query (the &#x0201c;SARS-PMC&#x0201d; and &#x0201c;HIV-PMC&#x0201d; corpora). We excluded reviews from further consideration. Using PubMed API, we collected the texts of over 6200 abstracts of PubMed and over 38,000 full texts of original articles in XML.</p><p>We used the automatically collected abstracts for the corpora &#x0201c;SARS-PubMed&#x0201d; and &#x0201c;HIV-PubMed&#x0201d; and the full texts collected for the corpora &#x0201c;SARS-PMC&#x0201d; and &#x0201c;HIV-PMC&#x0201d;. The texts represented in XML format were processed to save only the Materials and Methods, Results or Results and Discussion sections; the Introduction section was excluded. We used the abstracts of the &#x0201c;SARS-HIV-PubMed&#x0201d; corpus in the current study because the license agreement restricts the availability of full texts. It does not lead to a collection of unbiased corpora (i.e., corpora which are not limited by using several journals). Full texts of SARS-PMC and HIV-PMC were used for data extraction.</p><p>The collected corpora of abstracts were processed using Lingpipe-4.1.2 named entity algorithm trained on GENIA corpus [<xref rid="B77-molecules-25-02944" ref-type="bibr">77</xref>]. For evaluating the average accuracy of recognition, we applied five-fold cross-validation based on the corpus used for training the algorithm and an external test set &#x0201c;HIV-RT-inhibitor corpus&#x0201d; containing 250 abstracts. The average precision for Lingpipe-4.1.2 was 0.84%, the recall was 0.79.</p><p>After the extraction of the sets of proteins using all the corpora, we automatically compared them and identified overlapping proteins. According to our hypothesis, the proteins found in both sets of texts that were relevant (a) to HIV-1&#x02013;host interactions and (b) to SARS-host and SARS-CoV-2&#x02013;host interactions can influence the pathways and molecular mechanisms responsible for infection, invasion, and disease progression similarly or identically for HIV-1 and SARS-CoV-2.</p><p>The final set of proteins was checked using the UniProt API [<xref rid="B78-molecules-25-02944" ref-type="bibr">78</xref>,<xref rid="B79-molecules-25-02944" ref-type="bibr">79</xref>]. Only proteins found in UniProt and associated with <italic>Homo Sapiens</italic>, SARS-CoV-2, HIV-1 were saved in the list of proteins, which we analyzed further. The manual inspection of the proteins selected was carried out using NCBI PubMed electronic library and the UniProt, Protein Atlas, and Integrity databases.</p><p>To identify signaling pathways, first we manually mapped the initial entities, which were extracted by text-mining, to UniProt Accession numbers and obtained a list of 46 human proteins. Pathways enriched with 46 genes, were identified from the KEGG database [<xref rid="B18-molecules-25-02944" ref-type="bibr">18</xref>] using the &#x0201c;Enrichr&#x0201d; R package. We selected pathways which included at least 3 genes from the 46 ones and adjusted the <italic>p</italic>-value to less than 0.05. Visualization of the list of pathways was performed using the &#x0201c;Treemap&#x0201d; R package. Additionally, we identified diseases associated with 46 genes using Enrichr and gene&#x02013;disease associations using the DisGeNet database (<uri xlink:href="https://www.disgenet.org">https://www.disgenet.org</uri>) [<xref rid="B38-molecules-25-02944" ref-type="bibr">38</xref>].</p></sec><sec sec-type="conclusions" id="sec5-molecules-25-02944"><title>5. Conclusions</title><p>We demonstrated the usefulness of text and data mining techniques for finding human proteins involved in similar pathological processes involving well-known and novel viruses. We used the text and data mining techniques to identify possible molecular pathways common to two very distinct viruses, HIV-1 and SARS-CoV-2, as a case study. We extracted data for proteins related to the molecular mechanisms that may be essential for the development of the infections caused by SARS-CoV-2 and HIV-1 and demonstrated the usefulness of such application. We found a few key proteins that are known to be associated with mechanisms related to both HIV-1 and SARS-CoV-2 infections and to several different processes of pathogenesis, from virus entry to evasion of immune response and regulation of inflammation in the host. We considered the particular properties and molecular pathways that can be involved in different steps of HIV-1 and SARS-CoV-2 infections. We provided a few examples of therapies targeting some of the identified proteins. We showed that even these unrelated viruses can share the same human proteins and regulatory pathways, which should be taken into account for the development of treatment strategies based on existing drugs. We believe that the suggested approach can be used to select known drugs to be applied against novel viruses on the basis of shared regulatory pathways and protein targets.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Clarivate Analytics for the Academic Subscription to the Integrity database. We are thankful to Boris Sobolev (Institute of Biomedical Chemistry, Moscow, Russia) for the valuable comments regarding the content of the manuscript.</p></ack><app-group><app id="app1-molecules-25-02944"><title>Supplementary Materials</title><p>The following are available online, Figure S1: Four groups of diseases formed on the basis on gene-disease associations from DisGeNet database, Table S1: The list of human proteins identified as having impact on SARS-CoV-2 and HIV-1 infections development, Table S2: The proteins found as belonging to the set of validated targets for treatment pathological conditions and diseases according to the Integrity database, Table S3: List of human proteins involved in the development of the infection caused by SARS-CoV-1 according to the text and data mining.</p><supplementary-material content-type="local-data" id="molecules-25-02944-s001"><media xlink:href="molecules-25-02944-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Design of the study and text and data mining using Integrity database: O.T., computational experiments using KEGG and DisGeNet: S.I.; valuable comments and corrections D.A.F. and V.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by the Russian Science Foundation, grant number 19-75-10097. </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-25-02944"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>P.M.</given-names></name><name><surname>Hahn</surname><given-names>B.H.</given-names></name></person-group><article-title>Origins of HIV and the AIDS pandemic</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2011</year><volume>1</volume><fpage>a006841</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a006841</pub-id><?supplied-pmid 22229120?><pub-id pub-id-type="pmid">22229120</pub-id></element-citation></ref><ref id="B2-molecules-25-02944"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabish</surname><given-names>S.A.</given-names></name></person-group><article-title>COVID-19 pandemic: Emerging perspectives and future trends</article-title><source>J. Public Health Res.</source><year>2020</year><volume>9</volume><fpage>1786</fpage><pub-id pub-id-type="doi">10.4081/jphr.2020.1786</pub-id><?supplied-pmid 32550223?><pub-id pub-id-type="pmid">32550223</pub-id></element-citation></ref><ref id="B3-molecules-25-02944"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D.E.</given-names></name><name><surname>Jang</surname><given-names>G.M.</given-names></name><name><surname>Bouhaddou</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Obernier</surname><given-names>K.</given-names></name><name><surname>White</surname><given-names>K.M.</given-names></name><name><surname>O&#x02019;Meara</surname><given-names>M.J.</given-names></name><name><surname>Rezelj</surname><given-names>V.V.</given-names></name><name><surname>Guo</surname><given-names>J.Z.</given-names></name><name><surname>Swaney</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id><?supplied-pmid 32353859?><pub-id pub-id-type="pmid">32353859</pub-id></element-citation></ref><ref id="B4-molecules-25-02944"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>R.K.</given-names></name><name><surname>DiPaola</surname><given-names>R.S.</given-names></name><name><surname>Romanelli</surname><given-names>F.</given-names></name><name><surname>Dutch</surname><given-names>R.E.</given-names></name></person-group><article-title>Rapid repurposing of drugs for COVID-19</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>829</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1126/science.abb9332</pub-id><?supplied-pmid 32385101?><pub-id pub-id-type="pmid">32385101</pub-id></element-citation></ref><ref id="B5-molecules-25-02944"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciliberto</surname><given-names>G.</given-names></name><name><surname>Mancini</surname><given-names>R.</given-names></name><name><surname>Paggi</surname><given-names>M.G.</given-names></name></person-group><article-title>Drug repurposing against COVID-19: Focus on anticancer agents</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2020</year><volume>39</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/s13046-020-01590-2</pub-id><?supplied-pmid 32398164?><pub-id pub-id-type="pmid">32398164</pub-id></element-citation></ref><ref id="B6-molecules-25-02944"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayad</surname><given-names>B.</given-names></name><name><surname>Sobhani</surname><given-names>M.</given-names></name><name><surname>Khodarahmi</surname><given-names>R.</given-names></name></person-group><article-title>Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?</article-title><source>Arch. Med. Res.</source><year>2020</year><fpage>S0188440920305518</fpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2020.04.018</pub-id></element-citation></ref><ref id="B7-molecules-25-02944"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsuliman</surname><given-names>T.</given-names></name><name><surname>Alasadi</surname><given-names>L.</given-names></name><name><surname>Alkharat</surname><given-names>B.</given-names></name><name><surname>Srour</surname><given-names>M.</given-names></name><name><surname>Alrstom</surname><given-names>A.</given-names></name></person-group><article-title>A review of potential treatments to date in COVID-19 patients according to the stage of the disease</article-title><source>Curr Res. Transl. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.retram.2020.05.004</pub-id></element-citation></ref><ref id="B8-molecules-25-02944"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawar</surname><given-names>A.Y.</given-names></name></person-group><article-title>Combating devastating COVID-19 by drug repurposing</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><fpage>105984</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105984</pub-id><pub-id pub-id-type="pmid">32305589</pub-id></element-citation></ref><ref id="B9-molecules-25-02944"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>R.J.</given-names></name><name><surname>Jha</surname><given-names>R.K.</given-names></name><name><surname>Amera</surname><given-names>G.M.</given-names></name><name><surname>Jain</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>E.</given-names></name><name><surname>Pathak</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>R.P.</given-names></name><name><surname>Muthukumaran</surname><given-names>J.</given-names></name><name><surname>Singh</surname><given-names>A.K.</given-names></name></person-group><article-title>Targeting SARS-CoV-2: A systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2&#x02032;-O-ribose methyltransferase</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1753577</pub-id></element-citation></ref><ref id="B10-molecules-25-02944"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parang</surname><given-names>K.</given-names></name><name><surname>El-Sayed</surname><given-names>N.S.</given-names></name><name><surname>Kazeminy</surname><given-names>A.J.</given-names></name><name><surname>Tiwari</surname><given-names>R.K.</given-names></name></person-group><article-title>Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E)</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>2343</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25102343</pub-id></element-citation></ref><ref id="B11-molecules-25-02944"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>N.</given-names></name><name><surname>Vitoria</surname><given-names>M.</given-names></name><name><surname>Rangaraj</surname><given-names>A.</given-names></name><name><surname>Norris</surname><given-names>S.L.</given-names></name><name><surname>Calmy</surname><given-names>A.</given-names></name><name><surname>Doherty</surname><given-names>M.</given-names></name></person-group><article-title>Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: Initial assessment</article-title><source>J. Int. AIDS Soc.</source><year>2020</year><volume>23</volume><fpage>e25489</fpage><pub-id pub-id-type="doi">10.1002/jia2.25489</pub-id><?supplied-pmid 32293807?><pub-id pub-id-type="pmid">32293807</pub-id></element-citation></ref><ref id="B12-molecules-25-02944"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.-W.</given-names></name><name><surname>Kim</surname><given-names>E.J.</given-names></name><name><surname>Kwon</surname><given-names>H.H.</given-names></name><name><surname>Jung</surname><given-names>C.Y.</given-names></name><name><surname>Kim</surname><given-names>K.C.</given-names></name><name><surname>Choe</surname><given-names>J.-Y.</given-names></name><name><surname>Hong</surname><given-names>H.-L.</given-names></name></person-group><article-title>Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019</article-title><source>Korean J. Intern. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.3904/kjim.2020.224</pub-id><?supplied-pmid 32536150?><pub-id pub-id-type="pmid">32536150</pub-id></element-citation></ref><ref id="B13-molecules-25-02944"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagopoulos</surname><given-names>P.</given-names></name><name><surname>Petrakis</surname><given-names>V.</given-names></name><name><surname>Panopoulou</surname><given-names>M.</given-names></name><name><surname>Trypsianis</surname><given-names>G.</given-names></name><name><surname>Penlioglou</surname><given-names>T.</given-names></name><name><surname>Pnevmatikos</surname><given-names>I.</given-names></name><name><surname>Papazoglou</surname><given-names>D.</given-names></name></person-group><article-title>Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection</article-title><source>J. Chemother.</source><year>2020</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1080/1120009X.2020.1775424</pub-id><?supplied-pmid 32530369?><pub-id pub-id-type="pmid">32530369</pub-id></element-citation></ref><ref id="B14-molecules-25-02944"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>W.G.</given-names></name><name><surname>Brito</surname><given-names>J.C.M.</given-names></name><name><surname>Overhage</surname><given-names>J.</given-names></name><name><surname>Nizer</surname><given-names>W.S.d.C.</given-names></name></person-group><article-title>The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): A systematic review</article-title><source>Arch. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00705-020-04693-5</pub-id><?supplied-pmid 32514689?><pub-id pub-id-type="pmid">32514689</pub-id></element-citation></ref><ref id="B15-molecules-25-02944"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name></person-group><article-title>SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41423-020-0424-9</pub-id></element-citation></ref><ref id="B16-molecules-25-02944"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>Y.-Q.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Miao</surname><given-names>H.</given-names></name></person-group><article-title>Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study</article-title><source>Signal. Transduct. Target. Ther.</source><year>2020</year><volume>5</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-0148-4</pub-id><pub-id pub-id-type="pmid">32296069</pub-id></element-citation></ref><ref id="B17-molecules-25-02944"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuzzi</surname><given-names>S.J.</given-names></name><name><surname>Thornton</surname><given-names>T.E.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Baker</surname><given-names>N.</given-names></name><name><surname>Lam</surname><given-names>W.I.</given-names></name><name><surname>O&#x02019;Banion</surname><given-names>C.P.</given-names></name><name><surname>Muratov</surname><given-names>E.N.</given-names></name><name><surname>Pozefsky</surname><given-names>D.</given-names></name><name><surname>Tropsha</surname><given-names>A.</given-names></name></person-group><article-title>Chemotext: A Publicly Available Web Server for Mining Drug&#x02013;Target&#x02013;Disease Relationships in PubMed</article-title><source>J. Chem. Inf. Model.</source><year>2018</year><volume>58</volume><fpage>212</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.7b00589</pub-id><pub-id pub-id-type="pmid">29300482</pub-id></element-citation></ref><ref id="B18-molecules-25-02944"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarasova</surname><given-names>O.A.</given-names></name><name><surname>Biziukova</surname><given-names>N.Y.</given-names></name><name><surname>Filimonov</surname><given-names>D.A.</given-names></name><name><surname>Poroikov</surname><given-names>V.V.</given-names></name><name><surname>Nicklaus</surname><given-names>M.C.</given-names></name></person-group><article-title>Data Mining Approach for Extraction of Useful Information About Biologically Active Compounds from Publications</article-title><source>J. Chem. Inf. Model.</source><year>2019</year><volume>59</volume><fpage>3635</fpage><lpage>3644</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b00164</pub-id><pub-id pub-id-type="pmid">31453694</pub-id></element-citation></ref><ref id="B19-molecules-25-02944"><label>19.</label><mixed-citation publication-type="web"><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://talk.ictvonline.org/">https://talk.ictvonline.org/</ext-link></comment></mixed-citation></ref><ref id="B20-molecules-25-02944"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Sang</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>S.-J.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name></person-group><article-title>HIV-1 did not contribute to the 2019-nCoV genome</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>378</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1727299</pub-id><pub-id pub-id-type="pmid">32056509</pub-id></element-citation></ref><ref id="B21-molecules-25-02944"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K.-C.</given-names></name><name><surname>Wang</surname><given-names>T.-Y.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name></person-group><article-title>Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e34240</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0034240</pub-id><pub-id pub-id-type="pmid">22479575</pub-id></element-citation></ref><ref id="B22-molecules-25-02944"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weydert</surname><given-names>C.</given-names></name><name><surname>De Rijck</surname><given-names>J.</given-names></name><name><surname>Christ</surname><given-names>F.</given-names></name><name><surname>Debyser</surname><given-names>Z.</given-names></name></person-group><article-title>Targeting Virus-host Interactions of HIV Replication</article-title><source>Curr. Top. Med. Chem.</source><year>2016</year><volume>16</volume><fpage>1167</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.2174/1568026615666150901115106</pub-id><pub-id pub-id-type="pmid">26324041</pub-id></element-citation></ref><ref id="B23-molecules-25-02944"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monaco</surname><given-names>D.C.</given-names></name><name><surname>Ende</surname><given-names>Z.</given-names></name><name><surname>Hunter</surname><given-names>E.</given-names></name></person-group><article-title>Virus-Host Gene Interactions Define HIV-1 Disease Progression</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2017</year><volume>407</volume><fpage>31</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/82_2017_33</pub-id><pub-id pub-id-type="pmid">28653187</pub-id></element-citation></ref><ref id="B24-molecules-25-02944"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astuti</surname><given-names>I.</given-names></name><name><surname>Ysrafil</surname></name></person-group><article-title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response</article-title><source>Diabetes Metab. Syndr.</source><year>2020</year><volume>14</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.04.020</pub-id><?supplied-pmid 32335367?><pub-id pub-id-type="pmid">32335367</pub-id></element-citation></ref><ref id="B25-molecules-25-02944"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titanji</surname><given-names>B.K.</given-names></name><name><surname>Pillay</surname><given-names>D.</given-names></name><name><surname>Jolly</surname><given-names>C.</given-names></name></person-group><article-title>Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1</article-title><source>J. Gen. Virol.</source><year>2017</year><volume>98</volume><fpage>821</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000728</pub-id><?supplied-pmid 28141491?><pub-id pub-id-type="pmid">28141491</pub-id></element-citation></ref><ref id="B26-molecules-25-02944"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Friedman</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Taupin</surname><given-names>V.</given-names></name><name><surname>Crooks</surname><given-names>G.M.</given-names></name><name><surname>Kohn</surname><given-names>D.B.</given-names></name><name><surname>Gregory</surname><given-names>P.D.</given-names></name><name><surname>Holmes</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo</article-title><source>Nat. Biotechnol.</source><year>2010</year><volume>28</volume><fpage>839</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1038/nbt.1663</pub-id><?supplied-pmid 20601939?><pub-id pub-id-type="pmid">20601939</pub-id></element-citation></ref><ref id="B27-molecules-25-02944"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>P.K.</given-names></name><name><surname>Ferreira</surname><given-names>L.M.R.</given-names></name><name><surname>Collins</surname><given-names>R.</given-names></name><name><surname>Meissner</surname><given-names>T.B.</given-names></name><name><surname>Boutwell</surname><given-names>C.L.</given-names></name><name><surname>Friesen</surname><given-names>M.</given-names></name><name><surname>Vrbanac</surname><given-names>V.</given-names></name><name><surname>Garrison</surname><given-names>B.S.</given-names></name><name><surname>Stortchevoi</surname><given-names>A.</given-names></name><name><surname>Bryder</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9</article-title><source>Cell Stem Cell</source><year>2014</year><volume>15</volume><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.10.004</pub-id><?supplied-pmid 25517468?><pub-id pub-id-type="pmid">25517468</pub-id></element-citation></ref><ref id="B28-molecules-25-02944"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>A.G.</given-names></name><name><surname>Chung</surname><given-names>C.-H.</given-names></name><name><surname>Atkins</surname><given-names>A.</given-names></name><name><surname>Dampier</surname><given-names>W.</given-names></name><name><surname>Khalili</surname><given-names>K.</given-names></name><name><surname>Nonnemacher</surname><given-names>M.R.</given-names></name><name><surname>Wigdahl</surname><given-names>B.</given-names></name></person-group><article-title>Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2940</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02940</pub-id><pub-id pub-id-type="pmid">30619107</pub-id></element-citation></ref><ref id="B29-molecules-25-02944"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>M.S.</given-names></name><name><surname>Pierson</surname><given-names>T.C.</given-names></name></person-group><article-title>The Challenges of Vaccine Development against a New Virus during a Pandemic</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.021</pub-id><pub-id pub-id-type="pmid">32407708</pub-id></element-citation></ref><ref id="B30-molecules-25-02944"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>P.K.</given-names></name><name><surname>Kaminski</surname><given-names>R.</given-names></name><name><surname>Bella</surname><given-names>R.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Mathews</surname><given-names>S.</given-names></name><name><surname>Ahooyi</surname><given-names>T.M.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Mancuso</surname><given-names>P.</given-names></name><name><surname>Sariyer</surname><given-names>R.</given-names></name><name><surname>Ferrante</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>2753</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10366-y</pub-id><pub-id pub-id-type="pmid">31266936</pub-id></element-citation></ref><ref id="B31-molecules-25-02944"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKee</surname><given-names>D.L.</given-names></name><name><surname>Sternberg</surname><given-names>A.</given-names></name><name><surname>Stange</surname><given-names>U.</given-names></name><name><surname>Laufer</surname><given-names>S.</given-names></name><name><surname>Naujokat</surname><given-names>C.</given-names></name></person-group><article-title>Candidate drugs against SARS-CoV-2 and COVID-19</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>157</volume><fpage>104859</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104859</pub-id><pub-id pub-id-type="pmid">32360480</pub-id></element-citation></ref><ref id="B32-molecules-25-02944"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perricone</surname><given-names>C.</given-names></name><name><surname>Triggianese</surname><given-names>P.</given-names></name><name><surname>Bartoloni</surname><given-names>E.</given-names></name><name><surname>Cafaro</surname><given-names>G.</given-names></name><name><surname>Bonifacio</surname><given-names>A.F.</given-names></name><name><surname>Bursi</surname><given-names>R.</given-names></name><name><surname>Perricone</surname><given-names>R.</given-names></name><name><surname>Gerli</surname><given-names>R.</given-names></name></person-group><article-title>The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19</article-title><source>J. Autoimmun.</source><year>2020</year><fpage>102468</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2020.102468</pub-id><pub-id pub-id-type="pmid">32317220</pub-id></element-citation></ref><ref id="B33-molecules-25-02944"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>S.F.</given-names></name><name><surname>Ho</surname><given-names>Y.C.</given-names></name></person-group><article-title>SARS-CoV-2: A storm is raging</article-title><source>J. Clin. Invest.</source><year>2020</year><volume>130</volume><fpage>2202</fpage><pub-id pub-id-type="doi">10.1172/JCI137647</pub-id><?supplied-pmid 32217834?><pub-id pub-id-type="pmid">32217834</pub-id></element-citation></ref><ref id="B34-molecules-25-02944"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clay</surname><given-names>C.C.</given-names></name><name><surname>Donart</surname><given-names>N.</given-names></name><name><surname>Fomukong</surname><given-names>N.</given-names></name><name><surname>Knight</surname><given-names>J.B.</given-names></name><name><surname>Overheim</surname><given-names>K.</given-names></name><name><surname>Tipper</surname><given-names>J.</given-names></name><name><surname>Van Westrienen</surname><given-names>J.</given-names></name><name><surname>Hahn</surname><given-names>F.</given-names></name><name><surname>Harrod</surname><given-names>K.S.</given-names></name></person-group><article-title>Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses</article-title><source>Immun. Ageing</source><year>2014</year><volume>11</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/1742-4933-11-4</pub-id><?supplied-pmid 24642138?><pub-id pub-id-type="pmid">24642138</pub-id></element-citation></ref><ref id="B35-molecules-25-02944"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Advances in COVID-19: The virus, the pathogenesis, and evidence-based control and therapeutic strategies</article-title><source>Front. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s11684-020-0773-x</pub-id><?supplied-pmid 32318975?><pub-id pub-id-type="pmid">32318975</pub-id></element-citation></ref><ref id="B36-molecules-25-02944"><label>36.</label><element-citation publication-type="journal"><article-title>The UniProt Consortium UniProt: The universal protein knowledgebase</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>D158</fpage><lpage>D169</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1099</pub-id><?supplied-pmid 27899622?><pub-id pub-id-type="pmid">27899622</pub-id></element-citation></ref><ref id="B37-molecules-25-02944"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Furumichi</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Morishima</surname><given-names>K.</given-names></name></person-group><article-title>KEGG: New perspectives on genomes, pathways, diseases and drugs</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>D353</fpage><lpage>D361</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id><pub-id pub-id-type="pmid">27899662</pub-id></element-citation></ref><ref id="B38-molecules-25-02944"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pi&#x000f1;ero</surname><given-names>J.</given-names></name><name><surname>Ram&#x000ed;rez-Anguita</surname><given-names>J.M.</given-names></name><name><surname>Sa&#x000fc;ch-Pitarch</surname><given-names>J.</given-names></name><name><surname>Ronzano</surname><given-names>F.</given-names></name><name><surname>Centeno</surname><given-names>E.</given-names></name><name><surname>Sanz</surname><given-names>F.</given-names></name><name><surname>Furlong</surname><given-names>L.I.</given-names></name></person-group><article-title>The DisGeNET knowledge platform for disease genomics: 2019 update</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>D845</fpage><lpage>D855</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1021</pub-id><pub-id pub-id-type="pmid">31680165</pub-id></element-citation></ref><ref id="B39-molecules-25-02944"><label>39.</label><element-citation publication-type="web"><article-title>Clarivate Analytics Integrity Home Page</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://integrity.clarivate.com/integrity/xmlxsl/">https://integrity.clarivate.com/integrity/xmlxsl/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-04-04">(accessed on 4 April 2020)</date-in-citation></element-citation></ref><ref id="B40-molecules-25-02944"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C.-S.</given-names></name><name><surname>Qi</surname><given-names>H.-Y.</given-names></name><name><surname>Boularan</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>N.-N.</given-names></name><name><surname>Abu-Asab</surname><given-names>M.</given-names></name><name><surname>Shelhamer</surname><given-names>J.H.</given-names></name><name><surname>Kehrl</surname><given-names>J.H.</given-names></name></person-group><article-title>SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>3080</fpage><lpage>3089</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303196</pub-id><pub-id pub-id-type="pmid">25135833</pub-id></element-citation></ref><ref id="B41-molecules-25-02944"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekaran</surname><given-names>P.</given-names></name><name><surname>Buckley</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>V.</given-names></name><name><surname>Wang</surname><given-names>L.Q.</given-names></name><name><surname>Kehrl</surname><given-names>J.H.</given-names></name><name><surname>Venkatesan</surname><given-names>S.</given-names></name></person-group><article-title>HIV-1 Nef impairs heterotrimeric G-protein signaling by targeting G&#x003b1;(i2) for degradation through ubiquitination</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>41481</fpage><lpage>41498</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.361782</pub-id><?supplied-pmid 23071112?><pub-id pub-id-type="pmid">23071112</pub-id></element-citation></ref><ref id="B42-molecules-25-02944"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Xing</surname><given-names>Y.</given-names></name><name><surname>Tu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Coronavirus membrane-associated papain-like proteases induce autophagy through interacting with Beclin1 to negatively regulate antiviral innate immunity</article-title><source>Protein Cell</source><year>2014</year><volume>5</volume><fpage>912</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1007/s13238-014-0104-6</pub-id><pub-id pub-id-type="pmid">25311841</pub-id></element-citation></ref><ref id="B43-molecules-25-02944"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapierre</surname><given-names>J.</given-names></name><name><surname>Rodriguez</surname><given-names>M.</given-names></name><name><surname>Ojha</surname><given-names>C.R.</given-names></name><name><surname>El-Hage</surname><given-names>N.</given-names></name></person-group><article-title>Critical Role of Beclin1 in HIV Tat and Morphine-Induced Inflammation and Calcium Release in Glial Cells from Autophagy Deficient Mouse</article-title><source>J. Neuroimmune Pharmacol.</source><year>2018</year><volume>13</volume><fpage>355</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/s11481-018-9788-3</pub-id><?supplied-pmid 29752681?><pub-id pub-id-type="pmid">29752681</pub-id></element-citation></ref><ref id="B44-molecules-25-02944"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassen</surname><given-names>N.C.</given-names></name><name><surname>Niemeyer</surname><given-names>D.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Martinelli</surname><given-names>S.</given-names></name><name><surname>Gassen</surname><given-names>A.</given-names></name><name><surname>Hafner</surname><given-names>K.</given-names></name><name><surname>Papies</surname><given-names>J.</given-names></name><name><surname>M&#x000f6;sbauer</surname><given-names>K.</given-names></name><name><surname>Zellner</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>5770</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13659-4</pub-id><?supplied-pmid 31852899?><pub-id pub-id-type="pmid">31852899</pub-id></element-citation></ref><ref id="B45-molecules-25-02944"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona-Gutierrez</surname><given-names>D.</given-names></name><name><surname>Bauer</surname><given-names>M.A.</given-names></name><name><surname>Zimmermann</surname><given-names>A.</given-names></name><name><surname>Kainz</surname><given-names>K.</given-names></name><name><surname>Hofer</surname><given-names>S.J.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name><name><surname>Madeo</surname><given-names>F.</given-names></name></person-group><article-title>Digesting the crisis: Autophagy and coronaviruses</article-title><source>Microb. Cell</source><year>2020</year><volume>7</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.15698/mic2020.05.715</pub-id><pub-id pub-id-type="pmid">32391393</pub-id></element-citation></ref><ref id="B46-molecules-25-02944"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pooladanda</surname><given-names>V.</given-names></name><name><surname>Thatikonda</surname><given-names>S.</given-names></name><name><surname>Godugu</surname><given-names>C.</given-names></name></person-group><article-title>The current understanding and potential therapeutic options to combat COVID-19</article-title><source>Life Sci.</source><year>2020</year><fpage>117765</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117765</pub-id><?supplied-pmid 32437797?><pub-id pub-id-type="pmid">32437797</pub-id></element-citation></ref><ref id="B47-molecules-25-02944"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>N.-H.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="B48-molecules-25-02944"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divani</surname><given-names>A.A.</given-names></name><name><surname>Andalib</surname><given-names>S.</given-names></name><name><surname>Di Napoli</surname><given-names>M.</given-names></name><name><surname>Lattanzi</surname><given-names>S.</given-names></name><name><surname>Hussain</surname><given-names>M.S.</given-names></name><name><surname>Biller</surname><given-names>J.</given-names></name><name><surname>McCullough</surname><given-names>L.D.</given-names></name><name><surname>Azarpazhooh</surname><given-names>M.R.</given-names></name><name><surname>Seletska</surname><given-names>A.</given-names></name><name><surname>Mayer</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights</article-title><source>J. Stroke Cerebrovasc. Dis.</source><year>2020</year><volume>29</volume><fpage>104941</fpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2020.104941</pub-id></element-citation></ref><ref id="B49-molecules-25-02944"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshii</surname><given-names>H.</given-names></name><name><surname>Kamiyama</surname><given-names>H.</given-names></name><name><surname>Goto</surname><given-names>K.</given-names></name><name><surname>Oishi</surname><given-names>K.</given-names></name><name><surname>Katunuma</surname><given-names>N.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Hayashi</surname><given-names>H.</given-names></name><name><surname>Matsuyama</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>N.</given-names></name><etal/></person-group><article-title>CD4-independent human immunodeficiency virus infection involves participation of endocytosis and cathepsin B</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e19352</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0019352</pub-id><pub-id pub-id-type="pmid">21541353</pub-id></element-citation></ref><ref id="B50-molecules-25-02944"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lei</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Mi</surname><given-names>D.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1620</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="B51-molecules-25-02944"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Shi</surname><given-names>G.P.</given-names></name></person-group><article-title>Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients</article-title><source>Pharmacol. Ther.</source><year>2020</year><volume>213</volume><fpage>107587</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107587</pub-id></element-citation></ref><ref id="B52-molecules-25-02944"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>J.</given-names></name><name><surname>Yadavalli</surname><given-names>T.</given-names></name><name><surname>Agelidis</surname><given-names>A.M.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name></person-group><article-title>Host Enzymes Heparanase and Cathepsin L Promote Herpes Simplex Virus 2 Release from Cells</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><pub-id pub-id-type="doi">10.1128/JVI.01179-18</pub-id></element-citation></ref><ref id="B53-molecules-25-02944"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>L.E.</given-names></name><name><surname>Colon</surname><given-names>K.</given-names></name><name><surname>Cantres-Rosario</surname><given-names>Y.M.</given-names></name><name><surname>Zenon</surname><given-names>F.M.</given-names></name><name><surname>Melendez</surname><given-names>L.M.</given-names></name></person-group><article-title>Macrophage derived cystatin B/cathepsin B in HIV replication and neuropathogenesis</article-title><source>Curr. HIV Res.</source><year>2014</year><volume>12</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.2174/1570162X12666140526120249</pub-id><pub-id pub-id-type="pmid">24862331</pub-id></element-citation></ref><ref id="B54-molecules-25-02944"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantres-Rosario</surname><given-names>Y.M.</given-names></name><name><surname>Ortiz-Rodr&#x000ed;guez</surname><given-names>S.C.</given-names></name><name><surname>Santos-Figueroa</surname><given-names>A.G.</given-names></name><name><surname>Plaud</surname><given-names>M.</given-names></name><name><surname>Negron</surname><given-names>K.</given-names></name><name><surname>Cotto</surname><given-names>B.</given-names></name><name><surname>Langford</surname><given-names>D.</given-names></name><name><surname>Melendez</surname><given-names>L.M.</given-names></name></person-group><article-title>HIV Infection Induces Extracellular Cathepsin B Uptake and Damage to Neurons</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>8006</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-44463-1</pub-id><pub-id pub-id-type="pmid">31142756</pub-id></element-citation></ref><ref id="B55-molecules-25-02944"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantres-Rosario</surname><given-names>Y.</given-names></name><name><surname>Plaud-Valent&#x000ed;n</surname><given-names>M.</given-names></name><name><surname>Gerena</surname><given-names>Y.</given-names></name><name><surname>Skolasky</surname><given-names>R.L.</given-names></name><name><surname>Wojna</surname><given-names>V.</given-names></name><name><surname>Mel&#x000e9;ndez</surname><given-names>L.M.</given-names></name></person-group><article-title>Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders</article-title><source>AIDS</source><year>2013</year><volume>27</volume><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32835b3e47</pub-id><?supplied-pmid 23291538?><pub-id pub-id-type="pmid">23291538</pub-id></element-citation></ref><ref id="B56-molecules-25-02944"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Gao</surname><given-names>T.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name></person-group><article-title>The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><pub-id pub-id-type="doi">10.1128/JVI.02143-16</pub-id><?supplied-pmid 28148787?><pub-id pub-id-type="pmid">28148787</pub-id></element-citation></ref><ref id="B57-molecules-25-02944"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Tu</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name></person-group><article-title>TRIM25 Is Required for the Antiviral Activity of Zinc Finger Antiviral Protein</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e00088-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.00088-17</pub-id><?supplied-pmid 28202764?><pub-id pub-id-type="pmid">28202764</pub-id></element-citation></ref><ref id="B58-molecules-25-02944"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Mohammed</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Biochemical characterization of SARS-CoV-2 nucleocapsid protein</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2020</year><volume>527</volume><fpage>618</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.04.136</pub-id><pub-id pub-id-type="pmid">32416961</pub-id></element-citation></ref><ref id="B59-molecules-25-02944"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soy</surname><given-names>M.</given-names></name><name><surname>Keser</surname><given-names>G.</given-names></name><name><surname>Atag&#x000fc;nd&#x000fc;z</surname><given-names>P.</given-names></name><name><surname>Tabak</surname><given-names>F.</given-names></name><name><surname>Atag&#x000fc;nd&#x000fc;z</surname><given-names>I.</given-names></name><name><surname>Kayhan</surname><given-names>S.</given-names></name></person-group><article-title>Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment</article-title><source>Clin. Rheumatol.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s10067-020-05190-5</pub-id><?supplied-pmid 32474885?><pub-id pub-id-type="pmid">32474885</pub-id></element-citation></ref><ref id="B60-molecules-25-02944"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissinen</surname><given-names>L.</given-names></name><name><surname>K&#x000e4;h&#x000e4;ri</surname><given-names>V.-M.</given-names></name></person-group><article-title>Matrix metalloproteinases in inflammation</article-title><source>Biochim. Biophys. Acta.</source><year>2014</year><volume>1840</volume><fpage>2571</fpage><lpage>2580</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2014.03.007</pub-id><?supplied-pmid 24631662?><pub-id pub-id-type="pmid">24631662</pub-id></element-citation></ref><ref id="B61-molecules-25-02944"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muema</surname><given-names>D.M.</given-names></name><name><surname>Akilimali</surname><given-names>N.A.</given-names></name><name><surname>Ndumnego</surname><given-names>O.C.</given-names></name><name><surname>Rasehlo</surname><given-names>S.S.</given-names></name><name><surname>Durgiah</surname><given-names>R.</given-names></name><name><surname>Ojwach</surname><given-names>D.B.A.</given-names></name><name><surname>Ismail</surname><given-names>N.</given-names></name><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Moodley</surname><given-names>A.</given-names></name><name><surname>Dong</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection</article-title><source>BMC Med.</source><year>2020</year><volume>18</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-020-01529-6</pub-id><?supplied-pmid 32209092?><pub-id pub-id-type="pmid">32209092</pub-id></element-citation></ref><ref id="B62-molecules-25-02944"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Morrison</surname><given-names>T.E.</given-names></name><name><surname>Menachery</surname><given-names>V.D.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Whitmore</surname><given-names>A.</given-names></name><name><surname>Heise</surname><given-names>M.T.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis</article-title><source>mBio</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.1128/mBio.01753-18</pub-id><?supplied-pmid 30301856?><pub-id pub-id-type="pmid">30301856</pub-id></element-citation></ref><ref id="B63-molecules-25-02944"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitkiewicz</surname><given-names>J.</given-names></name><name><surname>Borjabad</surname><given-names>A.</given-names></name><name><surname>Morgello</surname><given-names>S.</given-names></name><name><surname>Murray</surname><given-names>J.</given-names></name><name><surname>Chao</surname><given-names>W.</given-names></name><name><surname>Emdad</surname><given-names>L.</given-names></name><name><surname>Fisher</surname><given-names>P.B.</given-names></name><name><surname>Potash</surname><given-names>M.J.</given-names></name><name><surname>Volsky</surname><given-names>D.J.</given-names></name></person-group><article-title>HIV induces expression of complement component C3 in astrocytes by NF-&#x003ba;B-dependent activation of interleukin-6 synthesis</article-title><source>J. Neuroinflammation</source><year>2017</year><volume>14</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s12974-017-0794-9</pub-id><?supplied-pmid 28122624?><pub-id pub-id-type="pmid">28122624</pub-id></element-citation></ref><ref id="B64-molecules-25-02944"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huson</surname><given-names>M.A.M.</given-names></name><name><surname>Wouters</surname><given-names>D.</given-names></name><name><surname>van Mierlo</surname><given-names>G.</given-names></name><name><surname>Grobusch</surname><given-names>M.P.</given-names></name><name><surname>Zeerleder</surname><given-names>S.S.</given-names></name><name><surname>van der Poll</surname><given-names>T.</given-names></name></person-group><article-title>HIV Coinfection Enhances Complement Activation During Sepsis</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>212</volume><fpage>474</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv074</pub-id><?supplied-pmid 25657259?><pub-id pub-id-type="pmid">25657259</pub-id></element-citation></ref><ref id="B65-molecules-25-02944"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastaglio</surname><given-names>S.</given-names></name><name><surname>Ruggeri</surname><given-names>A.</given-names></name><name><surname>Risitano</surname><given-names>A.M.</given-names></name><name><surname>Angelillo</surname><given-names>P.</given-names></name><name><surname>Yancopoulou</surname><given-names>D.</given-names></name><name><surname>Mastellos</surname><given-names>D.C.</given-names></name><name><surname>Huber-Lang</surname><given-names>M.</given-names></name><name><surname>Piemontese</surname><given-names>S.</given-names></name><name><surname>Assanelli</surname><given-names>A.</given-names></name><name><surname>Garlanda</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The first case of COVID-19 treated with the complement C3 inhibitor AMY-101</article-title><source>Clin. Immunol.</source><year>2020</year><volume>215</volume><fpage>108450</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2020.108450</pub-id><?supplied-pmid 32360516?><pub-id pub-id-type="pmid">32360516</pub-id></element-citation></ref><ref id="B66-molecules-25-02944"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>R.</given-names></name><name><surname>Qin</surname><given-names>X.</given-names></name></person-group><article-title>The good and evil of complement activation in HIV-1 infection</article-title><source>Cell Mol. Immunol.</source><year>2010</year><volume>7</volume><fpage>334</fpage><pub-id pub-id-type="doi">10.1038/cmi.2010.8</pub-id><pub-id pub-id-type="pmid">20228834</pub-id></element-citation></ref><ref id="B67-molecules-25-02944"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sironi</surname><given-names>M.</given-names></name><name><surname>Biasin</surname><given-names>M.</given-names></name><name><surname>Cagliani</surname><given-names>R.</given-names></name><name><surname>Forni</surname><given-names>D.</given-names></name><name><surname>De Luca</surname><given-names>M.</given-names></name><name><surname>Saulle</surname><given-names>I.</given-names></name><name><surname>Lo Caputo</surname><given-names>S.</given-names></name><name><surname>Mazzotta</surname><given-names>F.</given-names></name><name><surname>Mac&#x000ed;as</surname><given-names>J.</given-names></name><name><surname>Pineda</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>A common polymorphism in TLR3 confers natural resistance to HIV-1 infection</article-title><source>J. Immunol.</source><year>2012</year><volume>188</volume><fpage>818</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102179</pub-id><pub-id pub-id-type="pmid">22174453</pub-id></element-citation></ref><ref id="B68-molecules-25-02944"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huik</surname><given-names>K.</given-names></name><name><surname>Avi</surname><given-names>R.</given-names></name><name><surname>Pauskar</surname><given-names>M.</given-names></name><name><surname>Kallas</surname><given-names>E.</given-names></name><name><surname>J&#x000f5;geda</surname><given-names>E.-L.</given-names></name><name><surname>Karki</surname><given-names>T.</given-names></name><name><surname>Marsh</surname><given-names>K.</given-names></name><name><surname>Des Jarlais</surname><given-names>D.</given-names></name><name><surname>Uusk&#x000fc;la</surname><given-names>A.</given-names></name><name><surname>Lutsar</surname><given-names>I.</given-names></name></person-group><article-title>Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users</article-title><source>Infect. Genet. Evol.</source><year>2013</year><volume>20</volume><fpage>78</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2013.08.008</pub-id><pub-id pub-id-type="pmid">23962581</pub-id></element-citation></ref><ref id="B69-molecules-25-02944"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Banga</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Yasui</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Pantaleo</surname><given-names>G.</given-names></name><name><surname>Perreau</surname><given-names>M.</given-names></name><etal/></person-group><article-title>TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>4387</fpage><lpage>4396</lpage><pub-id pub-id-type="doi">10.1172/JCI99005</pub-id><pub-id pub-id-type="pmid">30148455</pub-id></element-citation></ref><ref id="B70-molecules-25-02944"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S.-Y.</given-names></name><name><surname>Osuna</surname><given-names>C.E.</given-names></name><name><surname>Hraber</surname><given-names>P.T.</given-names></name><name><surname>Hesselgesser</surname><given-names>J.</given-names></name><name><surname>Gerold</surname><given-names>J.M.</given-names></name><name><surname>Barnes</surname><given-names>T.L.</given-names></name><name><surname>Sanisetty</surname><given-names>S.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Lewis</surname><given-names>M.G.</given-names></name><name><surname>Geleziunas</surname><given-names>R.</given-names></name><etal/></person-group><article-title>TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy</article-title><source>Sci. Transl. Med.</source><year>2018</year><volume>10</volume><pub-id pub-id-type="doi">10.1126/scitranslmed.aao4521</pub-id></element-citation></ref><ref id="B71-molecules-25-02944"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallenave</surname><given-names>J.M.</given-names></name><name><surname>Guillot</surname><given-names>L.</given-names></name></person-group><article-title>Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1229</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01229</pub-id><pub-id pub-id-type="pmid">32574272</pub-id></element-citation></ref><ref id="B72-molecules-25-02944"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name></person-group><article-title>Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer</article-title><source>Ann. Transl. Med.</source><year>2020</year><volume>8</volume><fpage>244</fpage><pub-id pub-id-type="doi">10.21037/atm.2020.01.84</pub-id><pub-id pub-id-type="pmid">32309391</pub-id></element-citation></ref><ref id="B73-molecules-25-02944"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>C.</given-names></name><name><surname>Sharma</surname><given-names>A.R.</given-names></name><name><surname>Sharma</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>S.-S.</given-names></name></person-group><article-title>The Interplay among miRNAs, Major Cytokines, and Cancer-Related Inflammation</article-title><source>Mol. Ther. Nucleic Acids</source><year>2020</year><volume>20</volume><fpage>606</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2020.04.002</pub-id><?supplied-pmid 32348938?><pub-id pub-id-type="pmid">32348938</pub-id></element-citation></ref><ref id="B74-molecules-25-02944"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giat</surname><given-names>E.</given-names></name><name><surname>Ehrenfeld</surname><given-names>M.</given-names></name><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name></person-group><article-title>Cancer and autoimmune diseases</article-title><source>Autoimmun. Rev.</source><year>2017</year><volume>16</volume><fpage>1049</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2017.07.022</pub-id><?supplied-pmid 28778707?><pub-id pub-id-type="pmid">28778707</pub-id></element-citation></ref><ref id="B75-molecules-25-02944"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Q.</given-names></name><name><surname>Wyatt</surname><given-names>C.J.</given-names></name><name><surname>Han</surname><given-names>T.</given-names></name><name><surname>Smalley</surname><given-names>K.S.M.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name></person-group><article-title>ITCH as a potential therapeutic target in human cancers</article-title><source>Semin. Cancer Biol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.03.003</pub-id><?supplied-pmid 32165318?><pub-id pub-id-type="pmid">32165318</pub-id></element-citation></ref><ref id="B76-molecules-25-02944"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>A.Y.</given-names></name></person-group><article-title>Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.idc.2020.02.003</pub-id></element-citation></ref><ref id="B77-molecules-25-02944"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.-D.</given-names></name><name><surname>Ohta</surname><given-names>T.</given-names></name><name><surname>Tateisi</surname><given-names>Y.</given-names></name><name><surname>Tsujii</surname><given-names>J.</given-names></name></person-group><article-title>GENIA corpus--semantically annotated corpus for bio-textmining</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><issue>Suppl. 1</issue><fpage>180</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btg1023</pub-id></element-citation></ref><ref id="B78-molecules-25-02944"><label>78.</label><mixed-citation publication-type="web"><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.UniProt.org/help/api_queries">https://www.UniProt.org/help/api_queries</ext-link></comment></mixed-citation></ref><ref id="B79-molecules-25-02944"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudet</surname><given-names>P.</given-names></name><name><surname>Livstone</surname><given-names>M.S.</given-names></name><name><surname>Lewis</surname><given-names>S.E.</given-names></name><name><surname>Thomas</surname><given-names>P.D.</given-names></name></person-group><article-title>Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium</article-title><source>Brief. Bioinform.</source><year>2011</year><volume>12</volume><fpage>449</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1093/bib/bbr042</pub-id><pub-id pub-id-type="pmid">21873635</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="molecules-25-02944-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>KEGG pathways enriched in the genes associated with the human proteins found by our analysis. Each color represents an individual pathway. The size of each box reflects the number of proteins involved in that particular pathway. The number of proteins involved in each pathway is given in brackets.</p></caption><graphic xlink:href="molecules-25-02944-g001"/></fig><fig id="molecules-25-02944-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>KEGG pathways enriched in the genes associated with human proteins involved in both SARS-CoV-2&#x02013;host and Dengue&#x02013;host interactions. Each color represents an individual pathway. The size of each box reflects the number of proteins involved in that particular pathway. The number of proteins involved in each pathway is given in brackets.</p></caption><graphic xlink:href="molecules-25-02944-g002"/></fig><fig id="molecules-25-02944-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The Toll-like receptor signaling pathway includes the highest number of the proteins identified, related to immune system pathways and appearing in both SARS-CoV-2 and HIV-1 infections.</p></caption><graphic xlink:href="molecules-25-02944-g003"/></fig><fig id="molecules-25-02944-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The distribution of diseases and pathological conditions by the number of protein targets associated with them.</p></caption><graphic xlink:href="molecules-25-02944-g004"/></fig><fig id="molecules-25-02944-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>General scheme of the data extraction and analysis.</p></caption><graphic xlink:href="molecules-25-02944-g005"/></fig><table-wrap id="molecules-25-02944-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-25-02944-t001_Table 1</object-id><label>Table 1</label><caption><p>Examples of proteins that can have a role in both HIV-1 and severe acute respiratory syndrome (SARS)-coronavirus (CoV-2) infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">UniProt ID <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tissue <sup>3</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Process</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">AIP4</td><td align="center" valign="middle" rowspan="1" colspan="1">Q96J02</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Homo sapiens</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Widely expressed</td><td align="center" valign="middle" rowspan="1" colspan="1">Inflammation</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Beclin 1</td><td align="center" valign="middle" rowspan="1" colspan="1">Q14457</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Homo sapiens <sup>1</sup></italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Ubiquitous</td><td align="center" valign="middle" rowspan="1" colspan="1">Autophagy of immune cells</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cathepsin B</td><td align="center" valign="middle" rowspan="1" colspan="1">P07858</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Homo sapiens</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Widely expressed</td><td align="center" valign="middle" rowspan="1" colspan="1">Entry of the virus Viral replication (HIV-1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cathepsin L</td><td align="center" valign="middle" rowspan="1" colspan="1">Q5K630</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Homo sapiens</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Widely expressed</td><td align="center" valign="middle" rowspan="1" colspan="1">Entry of the virus</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Complement C3</td><td align="center" valign="middle" rowspan="1" colspan="1">P01024</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Homo sapiens</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Blood plasma and over 200 tissues</td><td align="center" valign="middle" rowspan="1" colspan="1">Immune response<break/>Inflammation<break/>Complement activation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFITM1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P13164</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Homo sapiens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone and over 200 tissues</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune response</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1,2,3</sup> UniProt ID, species, tissue are the identifiers of proteins in UniProt database.</p></fn></table-wrap-foot></table-wrap></floats-group></article>